Felix has decided to step down from her position as chief executive and director of the company immediately, after beginning a period of medical leave in July. Her employment will cease on 29 September. The board is currently in the process of searching for a permanent chief executive, expected to be appointed in the coming months. In the meantime, Charlie Rozes will continue as the acting chief executive and chief financial officer.
The chair of IG Group, Mike McTighe, expressed gratitude for Felix’s leadership and wished her well in her recovery. He acknowledged her significant contribution to the company over the past eight years, especially during her five-year tenure as group CEO. Under Felix’s guidance, the company successfully pursued a strategy to diversify its business while strengthening its core OTC business, resulting in a doubling of revenue and profit.
Felix joined IG Group as the chief executive in October 2018, previously having served as a non-executive director from September 2015. Her previous senior positions include roles at Verifone, IBM, and Citibank. Expressing her gratitude, Felix acknowledged the talented and ambitious individuals she had the privilege to lead, highlighting the collective effort that contributed to building a stronger and more diverse company.
In July, IG Group reported a decline in net profit for its 2023 financial year despite achieving record revenue. The total revenue for the 12-month period ending on 31 May exceeded £1.02bn, marking a 5% increase from the previous year and establishing a fourth consecutive financial year of record revenue. The rise in revenue was primarily attributed to a significant increase in interest income, which surged from £800,000 in FY22 to €80.8m. IG Group attributed this growth to higher interest rates in the market.
